Researchers have published an article outlining that the Cancer Drugs Fund (CDF), a Government policy designed to provide access to […]
The National Institute for Health and Care Excellence (NICE) has issued a draft “no” on ixazomib (Ninlaro®) for the treatment of patients with relapsed or refractory […]
The National Institute for Health and Care Excellence (NICE) has today published draft negative guidance on daratumumab (Darzalex®) monotherapy used […]
Cancer charity Myeloma UK, has launched MUK eleven, a first of its kind immunotherapy trial which aims to modulate the immune system to target myeloma. The Phase 1b trial will study oncolytic virus, Reolysin® (pelareorep), in combination with immunomodulatory drugs (IMiDs) as a rescue treatment in relapsing myeloma patients.
Myeloma UK has expressed disappointment at news that proposals to introduce a £20m budget impact test for new medicines approved […]
Myeloma UK Policy and Public Affairs Manager Kate Morgan commented, “Myeloma UK made a strong case to the Scottish Medicines Consortium for the approval of both indications and we are very disappointed by the decision not to recommend them for use.
After 20 years of outstanding service, Eric Low has announced that he is moving on from his post as Chief […]
TRIAL RESULTS SHOW SIGNIFICANT INCREASE IN MYELOMA PATIENT REMISSION Data from the largest Phase III trial ever conducted in myeloma […]
Myeloma UK carer survey findings suggest that emotional, mental and physical factors, combined with a lack of support and awareness […]
Ninlaro® (ixazomib), a new treatment for myeloma, has been granted a licence by the European Commission. It is specifically approved […]